HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug evaluation: E-5564.

Abstract
Eisai Co Ltd is developing the injectable endotoxin antagonist E-5564, for the potential prevention of the pathophysiological effects of endotoxin-mediated responses caused by bacterial infection, including septic shock.
AuthorsHari Kumar Ondiveeran, Alison Fox-Robichaud
JournalIDrugs : the investigational drugs journal (IDrugs) Vol. 7 Issue 6 Pg. 582-90 (Jun 2004) ISSN: 1369-7056 [Print] England
PMID15197664 (Publication Type: Journal Article, Review)
Chemical References
  • E5564
  • Endotoxins
  • Lipid A
Topics
  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Endotoxemia (drug therapy)
  • Endotoxins (antagonists & inhibitors)
  • Humans
  • Lipid A (adverse effects, analogs & derivatives, metabolism, pharmacokinetics, pharmacology, therapeutic use, toxicity)
  • Randomized Controlled Trials as Topic
  • Sepsis (drug therapy)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: